Abstract
With the successful use of gefitinib and erlotinib in clinic, some potent EGFR tyrosine kinase receptor inhibitors have gained widespread concern in the treatment of ovarian or non-small-cell lung cancer. However, the emergence of EGFR-activating mutations resist to the drugs, there is an impending need to design new inhibitor targeted EGFR. Furthermore, the understanding of mutual effect between EGFR and drug has been available, it has become a hot spot for the research of anticancer drugs. We have designed and synthesized a series of 6-methoxy-7-(3-morpholinopropoxy)-1-(2- phenoxyethyl)-quinoxalin-2(1H)-one derivatives as novel EGFR inhibitors. Most of the compounds have showed inhibitory activity toward EGFR kinase. This work has demonstrated it is possible to construct a new type of EGFR protein kinase inhibitor using a designin strategy.
Keywords: Anticancer, EGFR inhibitor, kinase assay, molecular docking, quinazolin-2(1H)-one, tyrosine kinase.
Graphical Abstract
Anti-Cancer Agents in Medicinal Chemistry
Title:Design, Synthesis and Biological Evaluation of Quinoxalin-2(1H)-one Derivatives as EGFR Tyrosine Kinase Inhibitors
Volume: 15 Issue: 2
Author(s): Xuemei Qin, Xiao Han, Liming Hu, Zhipeng Li, Zhufeng Geng, Zhanyang Wang, Chengchu Zeng and Xiangqian Xiao
Affiliation:
Keywords: Anticancer, EGFR inhibitor, kinase assay, molecular docking, quinazolin-2(1H)-one, tyrosine kinase.
Abstract: With the successful use of gefitinib and erlotinib in clinic, some potent EGFR tyrosine kinase receptor inhibitors have gained widespread concern in the treatment of ovarian or non-small-cell lung cancer. However, the emergence of EGFR-activating mutations resist to the drugs, there is an impending need to design new inhibitor targeted EGFR. Furthermore, the understanding of mutual effect between EGFR and drug has been available, it has become a hot spot for the research of anticancer drugs. We have designed and synthesized a series of 6-methoxy-7-(3-morpholinopropoxy)-1-(2- phenoxyethyl)-quinoxalin-2(1H)-one derivatives as novel EGFR inhibitors. Most of the compounds have showed inhibitory activity toward EGFR kinase. This work has demonstrated it is possible to construct a new type of EGFR protein kinase inhibitor using a designin strategy.
Export Options
About this article
Cite this article as:
Qin Xuemei, Han Xiao, Hu Liming, Li Zhipeng, Geng Zhufeng, Wang Zhanyang, Zeng Chengchu and Xiao Xiangqian, Design, Synthesis and Biological Evaluation of Quinoxalin-2(1H)-one Derivatives as EGFR Tyrosine Kinase Inhibitors, Anti-Cancer Agents in Medicinal Chemistry 2015; 15 (2) . https://dx.doi.org/10.2174/187152061502150116173357
DOI https://dx.doi.org/10.2174/187152061502150116173357 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
ADAM17 as a Therapeutic Target in Multiple Diseases
Current Pharmaceutical Design The Role of Pemetrexed in Lung Adenocarcinoma, Mixed Subtype with Bronchioloalveolar Carcinoma Features
Current Drug Targets The Superior Antitumor Effect of Self-Assembled Paclitaxel Nanofilaments for Lung Cancer Cells
Current Drug Delivery Simultaneous Determination of Cytochrome P450 Oxidation Capacity in Humans: A Review on the Phenotyping Cocktail Approach
Current Pharmaceutical Biotechnology Matrix Metalloproteinases
Current Medicinal Chemistry Pharmacogenetics of Childhood Acute Lymphoblastic Leukemia
Current Pharmacogenomics Investigating ABCB1-Mediated Drug-Drug Interactions: Considerations for In vitro and In vivo Assay Design
Current Drug Metabolism Monoclonal Antibodies: New Therapeutic Agents for Autoimmune Hemolytic Anemia?
Endocrine, Metabolic & Immune Disorders - Drug Targets Silver Nanomaterials in Contemporary Molecular Physiology Research
Current Medicinal Chemistry Transbronchial Needle Aspiration (TBNA): Past Present and Future
Current Respiratory Medicine Reviews Pharmacogenomics of Nicotine Dependence and Impact on Smoking Cessation
Current Pharmacogenomics Glucocorticoids and Vascular Reactivity
Current Vascular Pharmacology Targeting miR-21 Induces Autophagy and Chemosensitivity of Leukemia Cells
Current Drug Targets Nanoparticle-based Drug Delivery Systems for Targeted Epigenetics Cancer Therapy
Current Drug Targets Prostate Cancer Horizons in the Development of Novel Anti-Cancer Strategies
Current Medicinal Chemistry - Anti-Cancer Agents Neuroprotective Role of Natural Polyphenols
Current Topics in Medicinal Chemistry The Role of Soluble 5'-Nucleotidases in the Conversion of Nucleotide Analogs: Metabolic and Therapeutic Aspects
Current Medicinal Chemistry Implications of Nanoscale Based Drug Delivery Systems in Delivery and Targeting Tubulin Binding Agent, Noscapine in Cancer Cells
Current Drug Metabolism The Use of SIFT-MS to Investigate Headspace Aldehydes as Markers of Lipid Peroxidation
Current Analytical Chemistry Exploitation of Apoptosis Pathways for Childhood Leukemia
Current Pediatric Reviews